My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Ozagrel
    Ozagrel

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0818
    CAS #: 82571-53-7Purity ≥98%

    Description: Ozagrel (OKY046; KCT-0809; OKY046; Cataclot; KCT0809; Xanbo),an antiplatelet agent, is a potent and selective inhibitor of thromboxane A2 (TXA2 synthetase (IC50 = 11 nM) with antiplatelet activity. It has the potential use for for the improving postoperative cerebrovascular contraction and accompanying cerebral ischaemia.  

    References: J Pharmacol Sci. 2009 Oct;111(2):211-5; Pharmacology. 1999 Nov;59(5):257-65.

    Related CAS #: 189224-26-8 (sodium); 82571-53-7 (free base)  

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)228.25
    FormulaC13H12N2O2
    CAS No.82571-53-7
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 46 mg/mL (201.5 mM)
    Water:<1 mg/mL
    Ethanol:<1 mg/mL
    Other info

    Chemical Name: (E)-3-(4-((1H-imidazol-1-yl)methyl)phenyl)acrylic acid

    InChi Key: SHZKQBHERIJWAO-AATRIKPKSA-N

    InChi Code: InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+

    SMILES Code: O=C(/C=C/C1=CC=C(C=C1)CN2C=CN=C2)O

    SynonymsOzagrel Sodium; OKY-046;  OKY046; OKY 046; Ozagrel; KCT-0809; KCT 0809; KCT0809; Cataclot; Xanbo; Ozagrel free acid


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity:  Ozagrel increased 6-keto-PGF1 alpha, one of stable metabolites of PGI2, in various isolated cells and tissues perhaps via accumulated PG endoperoxides resulted by the inhibition of TXA2 synthase.

    In VivoOzagrel prevents oleic acid (OA) induced thromboxane A(2) generation and subsequently increased total protein concentration and the numbers of macrophages and neutrophils in bronchoalveolar lavage fluid and increased monocyte chemoattractant protein-1 andinterleukin-8 mRNA expression in the whole lung of guinea pigs. Ozagrel (3 mg/kg) decreases both the area and volume of the cortical infarction after ischemia-reperfusion of the middle cerebral artery in rat. Ozagrel also has suppressive effects on the neurologic deficits in the microthrombosis rat model. Ozagrel improves the reduced spontaneously locomotor activity and the obstruction of motor coordination in the conscious cerebral ischemia-reperfusion mouse model. Ozagrel suppresses the decrease in specific gravity of the brain tissue induced by the occlusion-reperfusion in the conscious cerebral ischemia-reperfusion SHR model, and recovers the postischemic decrease in cortical PO(2) after middle cerebral artery occlusion-reperfusion in cats. Ozagrel also increases the level of 6-keto-PGF(1alpha), a metabolite of prostaglandin I(2) (PGI(2)), in the brain tissue after cerebral ischemia-reperfusion, and the administration of PGI(2) improves the reduced spontaneous locomotor activity in the conscious cerebral ischemia-reperfusion mouse model. Ozagrel administered intravenously 30 min before oleic acid injection prevents the decrease in Pao(2) and pulmonary vascular hyper-permeability in guinea-pigs. Ozagrel also prevents increases in lactate dehydrogenase activity, a measure of lung cell injury, TXB(2) and its weight ratio to 6-keto prostaglandin F(1alpha) in bronchoalveolar lavage fluid in guinea-pigs.
    Animal modelGuinea pigs
    Formulation & Dosage3 mg/kg
    References

    J Pharmacol Sci. 2009 Oct;111(2):211-5; Pharmacology. 1999 Nov;59(5):257-65.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Ozagrel


    Effects of ozagrel on serum ALT level and survival rate in APAP-induced liver injury. BMC Gastroenterol. 2013; 13: 21.


    Ozagrel

    Effects of ozagrel on hepatic cell death-related markers in liver induced by APAP injection. BMC Gastroenterol. 2013; 13: 21.



    Ozagrel

    Effects of ozagrel on hepatic GSH depletion induced by APAP and CYP 2E1 level. BMC Gastroenterol. 2013; 13: 21.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?